Robert W. Baird analyst Brian Skorney maintained a Hold rating on Arbutus Biopharma (ABUS) on March 16 and set a price target of $4.00. The company’s shares closed last Wednesday at $3.71.
According to TipRanks.com, Skorney is a 4-star analyst with an average return of 7.1% and a 53.4% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Intellia Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arbutus Biopharma with a $6.43 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $9.02 and a one-year low of $0.88. Currently, Arbutus Biopharma has an average volume of 3.23M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.
Read More on ABUS:
